MiMedx Group Inc
Change company Symbol lookup
Select an option...
MDXG MiMedx Group Inc
BHR Braemar Hotels & Resorts Inc
ESALY Eisai Co Ltd
CNX CNX Resources Corp
WW WW International Inc
IBM International Business Machines Corp
NEP Nextera Energy Partners LP
TMP Tompkins Financial Corp
MFM MFS Municipal Income Trust
HMNKF HMS Networks AB
Go

Health Care : Biotechnology | Small Cap Growth
Company profile

MiMedx Group, Inc. is an integrated developer, processor and marketer of regenerative biomaterial products and bioimplants human placental tissue, skin and bone. The Company's Regenerative Biomaterials segment includes the design, manufacture, and marketing of products and tissue processing services for the Wound Care, Surgical, Sports Medicine, Ophthalmic and Dental market categories. Its biomaterial platform technologies include AmnioFix, EpiFix, OrthoFlo, Physio, AlloBurn, and CollaFix. AmnioFix and EpiFix are its tissue technologies processed from human amniotic membrane derived from donated placentas. OrthoFlo is amniotic fluid-derived allograft for homologous use. Physio is a bone grafting material consists of bone tissue with no added carrier. CollaFix, its new brand, is its collagen fiber technology designed to mimic the natural composition, structure and mechanical properties of musculoskeletal tissues in order to augment their repair.

Closing Price
$5.86
Day's Change
-0.52 (-8.15%)
Bid
--
Ask
--
B/A Size
--
Day's High
6.37
Day's Low
5.52
Volume
(Heavy Day)
Volume:
242,793

10-day average volume:
151,562
242,793

Display:

Providers:

UpdateCancel
6 providers
October 15, 2020
MiMedx Files Definitive Proxy Materials

MiMedx Group, Inc. (OTC PINK: MDXG) ("MiMedx" or "the Company"), an industry leader in advanced wound care and a therapeutic biologics company, today announced that it has filed a definitive proxy statement with the U.S. Securities and Exchange...(Globe Newswire)

September 21, 2020
MiMedx Concludes Enrollment for Phase 2B Study of Osteoarthritis (OA) of the Knee

Research Advances Understanding of Amniotic Tissue as Potential Unique Treatment for Painful Chronic Condition that Affects 242 Million People Globally MiMedx Group, Inc. (OTC PINK: MDXG) ("MiMedx" or "the Company"), an industry leader in advanced...(Globe Newswire)

September 17, 2020
MiMedx Concludes Enrollment for Phase 3 Plantar Fasciitis Trial

Research in Plantar Fasciitis Advances Understanding of Amniotic Tissue as Potential Treatment for Chronic Musculoskeletal Pain and Function Disorders MiMedx Group, Inc. (OTC PINK: MDXG) ("MiMedx" or "the Company"), an industry leader in advanced...(Globe Newswire)

September 14, 2020
MiMedx Launches EpiCord Expandable Placental Allograft as Addition to Market Leading Portfolio

New Allograft Expands to Twice its Size and Provides a Protective Structure to Support the Wound Healing Cascade MiMedx Group, Inc. (OTC PINK: MDXG) ("MiMedx" or "the Company"), an industry leader in advanced wound care and an emerging therapeutic...(Globe Newswire)

August 24, 2020
MiMedx to Discuss Strategic Priorities at Upcoming Virtual 2019 Annual Meeting of Shareholders

MiMedx Group, Inc. (OTC PINK: MDXG) ("MiMedx" or "the Company"), an industry leader in advanced wound care and an emerging therapeutic biologics company, today provided additional information about its upcoming virtual 2019 Annual Meeting of...(Globe Newswire)

August 10, 2020
MiMedx Welcomes Robert B. Stein, M.D., Ph.D., to Head Revitalized R&D Efforts

MiMedx Group, Inc. (OTC PINK: MDXG) ("MiMedx" or "the Company"), an industry leader in advanced wound care and an emerging therapeutic biologics company, today announced the addition of Robert B. Stein, M.D., Ph.D., as Executive Vice President...(Globe Newswire)

August 03, 2020
MiMedx Files Definitive Proxy Materials

MiMedx Group, Inc. (OTC PINK: MDXG) ("MiMedx" or "the Company"), an industry leader in advanced wound care and an emerging therapeutic biologics company, today announced that it has filed a definitive proxy statement with the U.S. Securities and...(Globe Newswire)

July 28, 2020
MiMedx Adds Rohit Kashyap, Ph.D., to Leadership Team as Executive Vice President and Chief Commercial Officer

MiMedx Group, Inc. (OTC PINK: MDXG) ("MiMedx" or "the Company"), an industry leader in advanced wound care and an emerging therapeutic biologics company, today announced the addition of Rohit Kashyap, Ph.D., as Executive Vice President and Chief...(Globe Newswire)

Earnings Calendar and Events Data provided by |Terms of Use| © 2020 Wall Street Horizon, Inc.

Market data accompanied by is delayed by at least 15 minutes for NASDAQ, NYSE MKT, NYSE, and options. Duration of the delay for other exchanges varies.
Market data and information provided by Morningstar.

Options are not suitable for all investors as the special risks inherent to options trading may expose investors to potentially rapid and substantial losses.
Please read Characteristics and Risks of Standard Options before investing in options.

"Hot" indicates urgent and noteworthy news stories as determined by providers Dow Jones or Benzinga. TD Ameritrade does not select or recommend "hot" stories.

Information and news provided by ,, , Computrade Systems, Inc., , and

Copyright © 2020. All rights reserved.